肝硬化是我国临床上的常见病，肝硬化失代偿期常出现明显腹水，预后不良，但恰当治疗不仅可以消退腹水，而且尚可防止其它合并症。本文报道我们观察的肝硬化门脉高压合并腹水患者２７０例，经试用新型免疫调节剂——抗乙肝胎盘肽，改善肝内炎症，同时合理使用利尿剂，补充蛋白等综合治疗，多数患者获得较好临床效果。 Cirrhosis is a common clinical disease in our country. The patients with decompensated liver cirrhosis often have obvious ascites and poor prognosis. However, proper treatment can not only reduce the ascites, but also prevent other complications. This article reports 270 cases of cirrhotic patients with portal hypertension and ascites observed in our study, the trial of a new immunomodulator - anti-hepatitis B placental peptide to improve intrahepatic inflammation, while rational use of diuretics, protein and other comprehensive treatment, the majority of patients were more Good clinical effect.